Безопасность лечения прямыми оральными антикоагулянтами больных с фибрилляцией предсердий и высоким риском инсульта (обзор литературы)

Литературный обзор посвящен проблеме безопасности применения прямых оральных антикоагулянтов у больных с неклапанной фибрилляцией предсердий. Обсуждаются критерии оценки риска кровотечений на фоне терапии антикоагулянтами, способы предупреждения больших кровотечений (внутричерепных, желудочно-кишечных) на фоне этой терапии, а также тактика ведения больных с кровотечениями, возникшими на фоне прямых оральных антикоагулянтов. Особое внимание уделяется выбору прямого орального антикоагулянта, значению доступного антагониста действия дабигатрана – идаруцизумаба, показаниям к применению этого препарата.

1. Atrial fibrillation, stroke risk, and warfarin therapy revisited: a population-based study / S. Bjorck, B. Palaszewski, L. Friberg, L. Bergfeldt // Stroke. – 2013. – Vol. 44. – P. 3103–3108. https://doi.org/10.1161/strokeaha.113.002329.

2. Krijthe B. P., Kunst A., Benjamin E. J. et al. Projections on the number of individuals with atrial fibrillation in the Eurioean Union, from 2000 to 2060 // Eur. Heart J. – 2013. – Vol. 34, № 35. – P. 2746–2751. https://doi.org/10.1093/eurheartj/eht280.

3. Go A. S., Mozaffarian D., Roger V. L. et al. Executive Summary: Heart Disease and Stroke Statistics 2014 Update. A Report From the American Heart Association // Circulation. – 2014. – Vol. 129, № 3. – Р. 399–410. https://doi.org/10.1161/01.cir.0000442015.53336.12.

4. Fisher M., Hill J. A. Ischemic Stroke Mandates CrossDisciplinary Collaboration // Stroke. – 2018. – Vol. 49. – P. 273–274. https://doi.org/10.1161/strokeaha.117.020014.

5. Kirchhof P., Benussi S., Kotecha D. et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS // Eur. Heart J. – 2016. – Vol. 37. – P. 2893–2962. https://doi.org/10.1093/eurheartj/ehw210.

6. Connolly S. J., Ezekowitz M. D., Yusuf S. et al. Dabigatran versus warfarin in patients with atrial fibrillation // N. Engl. J. Med. – 2009. – Vol. 361. – P. 1139–1151. https://doi.org/10.1056/nejmoa0905561.

7. Patel M., Mahaffey K. W., Garg J. et al. Rivaroxaban versus warfarin in non-valvular atrial fibrillation // N. Engl. J. Med. – 2011. – Vol. 365. – P. 883–891. https://doi.org/10.1056/nejmoa1009638.

8. Granger С., Alexander J. H., McMurray J. J. et al. Apixaban versus warfarin in patients with atrial fibrillation // N. Engl. J. Med. – 2011. – Vol. 365. – P. 981–992. https://doi.org/10.1056/nejmoa1107039.

9. Steffel J., Verhamme P., Potpara T. et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation // Eur. Heart J. – 2018. – Vol. 39. – P. 1330–1393. https://doi.org/10.1093/eurheartj/ehy136.

10. Ионин В. А., Петрищева Е. Ю., Скуридин Д. С. и др. Антикоагулянтная терапия и компоненты метаболического синдрома у пациентов с фибрилляцией предсердий // Мед. совет. – 2019. – № 5. – С. 60–63. https://doi.org/10.21518/2079-701X-2019-5-60-63.

11. Raparelli V., Proietti M., Candemi R. et al. Adherence to oral anticoagulant therapy in patients with atrial fibrillation // Thromb Haemost. – 2017. – Vol. 117, № 2. – Р. 209–218. https://doi.org/10.1160/th16-10-0757.

12. 2019 AHA/ACC/HRS Focused updated of the 2014 AHA/ACC/HRS Guideline for the management of patients with atrial fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons // Circulation. – 2019. – Vol. 140, № 2. – Р. e125–e151. https://doi.org/10.1161/cir.0000000000000665.

13. 2018 EOK/EOАГ Рекомендации по лечению больных с артериальной гипертензией // Рос. кардиол. журн. – 2018. – Т. 23, № 12. – С. 143–228. http://doi.org/10.15829/1560-4071-2018-12-143-228.

14. Lu V. M., Phan K., Prashanth J. R. et al. Dabigatran reversal by idarucizumab in the setting of intracranial hemorrhage: a systematic review of the literature // Clinical Neurol. Neurosurgery. – 2019. – Vol. 181. – P. 76–81. https://doi.org/10.1016/j.clineuro.2019.04.013.

15. Schulman S. Bleeding complications and management on anticoagulant therapy // Semin. Thromb. Haemost. – 2017. – Vol. 43, № 8. – Р. 886–892. https://doi.org/10.1055/s-0037-1602377.

16. Fanaroff A. C., Hasselblad V., Roe M. T. et al. Antithrombotic agents for secondary prevention after acute coronary syndromes: a systematic review and network meta-analysis // Intern. Journ. of Cardiology. – 2017. – Vol. 241. – P. 87–96. Doi: 10.1016/j.ijcard.2017.03.046.

17. Neumann F.-J., Sousa-Uva M., Ahlsson A. et al. 2018 ESC/ EACN Guidelines on myocardial revascularization // Eur. Heart J. – 2018. – Vol. 40. – P. 87–165. Doi: 10.1093.eurheartj/ehy394.

18. Ando G., Capranzano P. Non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients with chronic kidney disease: a systemic review and network meta-analysis // Int. J. Cardiol. – 2017. – Vol. 231. – P. 162–169. https://doi.org/10.1016/j.ijcard.2016.11.303.

19. A district general hospital experience of patients receiving apixaban, dabigatran, rivaroxaban or warfarin for anticoagulation / L. Raiman, H. Antbring, A. Abu-Sitta, F. N. AlRefaie // Blood. – 2016. – Vol. 128. – P. 4733.

20. The clinical impact of bleeding during oral anticoagulant therapy: assessment of morbidity, mortality and postbleed anticoagulant management / M. Guerrouij, C. S. Uppal, A. Alklabi, J. D. Douketis // J. Thromb Thrombolysis. – 2011. – Vol. 31. – P. 419–423. https://doi.org/10.1007/s11239-010-0536-7.

21. Marmo R., Koch M., Cipolletta L. et al. Italian registry on upper gastrointestinal bleeding. Predicting mortality in non-variceal upper gastrointestinal bleeders: validation of the Italian PNED score and prospective comparison with the Rockall score // Am. J. Gastroenterol. – 2010. – Vol. 105. – P. 1294–1291. https://doi.org/10.1038/ajg.2009.687.

22. Strate L. L., Gralnek I. M. ACG clinical guideline: management of patients with acute lower gastrointestinal bleeding // Am. J. Gastroenterol. – 2016. – Vol. 111. – P. 459–474. https://doi.org/10.1038/ajg.2016.41.

23. Lip G. Y. H., Clemens A., Noack H. et al. Patient outcomes using European label for dabigatran. A post-hoc analysis from the RE-LY database // Thromb Haemost. – 2014. – Vol. 111, № 5. – Р. 933–942. https://doi.org/10.1160/th13-09-0734.

24. Желудочно-кишечные кровотечения при использовании новых пероральных антикоагулянтов: эпидемиология, факторы риска, лечение и профилактика / Е. В. Мороз, А. Е. Каратеев, Е. В. Крюков, В. А. Чернецов // Научно-практ. ревматология. – 2017. – Т. 55, № 6. – С. 675–684.

25. Cheung K.-S., Leung W. K. Gastrointestinal bleeding in patients on novel oral anticoagulants: risk, prevention and management // World J. Gastroenterol. – 2017. – Vol. 23, № 11. – Р. 1954–1963. https://doi.org/10.3748/wjg.v23.i11.1954.

26. Zullo A., Hassan C., Radaelly F. Gastrointestinal endoscopy in patients on anticoagulant therapy and antiplatelet agents // Ann. Gastroenterol. 2017;30(1):7–14. https://doi.org/10.20524/aog.2016.0096.

27. Chan E. W., Lau W. C. Y., Leung W. K. et al. Prevention of dabigatran-related gastrointestinal bleeding with gastroprotective agents: a population-based study // Gastroenterology. – 2015. – Vol. 149. – P. 586–595. https://doi.org/10.1053/j.gastro.2015.05.002.

28. Pasin F., Testa S., Capone P. et al. Gastrointestinal bleeding during direct oral anticoagulantsanticoagulant therapy. Is there nothing so bad that is not good for something? // Eur. J. Intern. Med. – 2017. – Vol. 39. – P. e25–e26. https://doi.org/10.1016/j.ejim.2017.02.020.

29. Flack K. F., Desai J., Kolb J. M. et al. Major gastrointestinal bleeding often is caused by occult malignancy in patients receiving warfarin or dabigatran to prevent stroke and systemic embolism from atrial fibrillation // Clin. Gastroenterol. Hepatol. – 2017. – Vol. 15, № 5. – Р. 682–690. https://doi.org/10.1016/j.cgh.2016.10.011.

30. Баранова Е. И., Филатова А. Г., Ионин В. А. Как снизить риск желудочно-кишечных кровотечений на фоне терапии антикоагулянтами у больных с неклапанной фибрилляцией предсердий? // Рос. кардиол. журн. – 2017. – Т. 10, № 150. – С. 124–132.

31. Grottke O., Aisenberg J., Bernstein R. et al. Efficacy of prothrombin complex concentrates for the emergency reversal of dabigatran-induced anticoagulation // Crit Care. – 2016. – Vol. 20. – P. 115. https://doi.org/10.1186/s13054-016-1275-8.

32. Fries D., Giurea A., Gutl M. et al. Management of dabi gatran-induced bleeding expert statement // Wien Klin Wochenschr. – 2013. – Vol. 125. – P. 721–729. https://doi.org/10.1007/s00508-013-0430-3.

33. Yeh C. H., Hogg K., Weitz J. I. Overview of the new oral anticoagulants: opportunities and challenges // Arterioscler. Thromb Vasc. Biol. – 2015. – Vol. 35. – P. 1056–1065. https://doi.org/10.1161/atvbaha.115.303397.

34. Huisman M. V., Fanikos J. Idarucizumab and Factor Xa reversal agents: role in hospital guidelines and protocols // Am. J. Med. – 2016. – Vol. 129. – P. S89–S96. https://doi.org/10.1016/j.amjmed.2016.06.010.

35. Pollack C. V. Jr., Relly P. A., Ryan J. van et al. Idarucizumab for dabigatran reversal – full cohort analysis // N. Engl. J. Med. – 2017. – Vol. 377. – P. 431–441. https://doi.org/10.1056/nejmoa1707278.

36. Proietti M., Boriani G. Use of idarucizumab in reversing dabigatran anticoagulant effect: a critical appraisal // Therapeutis and Clinical Risk Management. – 2018. – Vol. 14. – P. 1483–1488. http://doi.org/10.2147/TCRM.S140377.

37. Glund S., Moschetti V., Norris S. et al. A randomized study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran // Thromb Haemost. – 2015. – Vol. 113. – P. 943–951. https://doi.org/10.1160/th14-12-1080.

38. Glund S., Stangier J., Schmohl M. et al. Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomized, placebo-controlled, double-blind phase 1 trial // Lancet. – 2015. – Vol. 386. – P. 680–690. https://doi.org/10.1016/s0140-6736(15)60732-2.

39. Glund S., Stangier J., Ryn J. van et al. Effect of age and renal function on idarucizumab pharmacokinetics and idarucizumab-mediated reversal of dabigatran anticoagulant activity in a randomized, double-blind, crossover phase Ib study // Clin. Pharmacokinet. – 2017. – Vol. 56. – P. 41–54. https://doi.org/10.1007/s40262-016-0417-0.

40. Schmohl M., Glund S., Harada A. et al. Idarucizumab does not have procoagulant effects: assessment of thrombosis biomarkers in healthy volunteers // Thromb Haemost. – 2017. – Vol. 26. – P. 269–276. https://doi.org/10.1160/th16-05-0385.

41. Wall S. J. van der, Rein N. van, Bemt B. van der et al. Performance of idarucizumab as antidote of dabigatran in daily clinical practice // EP Europace. – 2019. – Vol. 21. – P. 414–420. https://doi.org/10.1093/europace/euy220.

42. Sheikh-Taha M. Idarucizumab for reversal of dabigatran: single-center real-world experience // Am. J. Cardiovasc. Drugs. – 2019. – Vol. 19. – P. 59–64. Doi: 10.1007/s40256-018-0300-5.

43. Idarucizumab in patients treated with dabigatran suffering cerebral ischemia or intracranial hemorrhage: a retrospective case series from Germany / P. Kermer, C. C. Eschenfelder, H. C. Diener, M. Grond // Home Stroke. – 2019. – Vol. 50, Suppl. 1. – Abstr. 84. https://doi.org/10.1161/str.50.suppl_1.84.

44. Eikelboom J. W, Kozek-Langenecker S., Exadaktylos A. et al. Emergency care of patients receiving non-vitamin K antagonist oral anticoagulants // Brit. J. Anaest. – 2018. – Vol. 120, № 4. – Р. 645–656. Doi: 10.1016/j.bja.2017.11.082.

45. Факторы риска, особенности клинического течения и распространенность желчнокаменной болезни у лиц пожилого и старческого возраста в Москве / М. Е. Дорофеенков, Е. Д. Ли, О. О. Кузнецов, Ю. В. Конев // Клин. геронтология. – 2013. – № 3–4. – С. 30–35.

46. Brennan Y., Favaloro E., Pasalic L. et al. Lessons learnt from local real-life experience with idarucizumab for the reversal of dabigatran // Int. Med. J. – 2019. – Vol. 49. – P. 59–65. https://doi.org/10.1111/imj.13995.

47. Maruyama S., Hayakawa K., Kanayama S. et al. Idarucizumab for a traumatic head injury patient taking dabigatran // Int. J. Emergency Med. – 2018. – Vol. 11. – P. 41–44. Doi: 10.1186/s12245-018-0202-y.

48. Gawehn A., Ayari Y., Heuschkel C. et al. Successful thrombolysis with recombinant tissue plasminogen activator after antagonizing dabigatran by idarucizumab: a case report // J. Med. Case Rep. – 2016. – Vol. 10. – P. 269. Doi: 10.1186/s13256-01601050-0.

49. Kermer P., Eschenfelder C. C., Diener H. C. et al. Anta gonizing dabigatran by idarucizumab in case of ischemic stroke or intracranial hemorrhage in Germany – A nation case collection // Int. Stroke. – 2017. – Vol. 12. – P. 381–391. Doi: 10.1177/1747493017701944.

50. Intravenous thrombolysis with recombinant tissue-type plasminogen activator in a stroke patient receiving dabigatran anticoagulant after antagonization with idarucizumab / J. Berrouschot, A. Stoll, T. Hogh, C. C. Eschenfelder // Stroke. – 2016. – Vol. 47. – P. 1936–1938. Doi: 10.1161/STROKEAHA.116.013550.

51. Mutzenbach J. S., Pikija S., Otto F. et al. Intravenous thrombolysis in acute ischemic stroke after reversal with idarucizumab: a case report // Ann Clin Transl Neurol. – 2016. – Vol. 3. – P. 889–892. Doi: 10.1002/acn3.346.

52. Heo Y. A. Andexanet-alfa: first global approval // Drugs. – 2018. – Vol. 78. – P. 1049–1055. https://doi.org/10.1007/s40265-018-0940-4.

53. Non-vitamin K oral anticoagulants associated bleeding and its antidotes / T. Steiner, M. Kohrmann, P. Schellinger, G. Tsivgoulis // Journ. of Stroke. – 2018. – Vol. 20, № 3. – Р. 292–301. https://doi.org/10.5853/jos.2018.02250.

54. Siddiqui F., Tafur A., Ramacciotti L. S. et al. Reversal of Factor Xa inhibitors by andexanet alfa may increase thrombogenesis compared to pretreatment values // Clinical Applied Thrombosis Hemostasis. – 2019. – Vol. 25. – P. 1–7. https://doi.org/10.1177/1076029619863493.